Merck: positive results in endometrial cancer

(CercleFinance.com) - Merck yesterday announced the results of a Phase 3 trial of Keytruda, in combination with standard chemotherapy (carboplatin and paclitaxel), followed by monotherapy every six weeks for up to 14 cycles, for the first-line treatment of selected patients with stage III-IV or recurrent endometrial cancer.


The trial results showed that the Keytruda regimen demonstrated a statistically and clinically significant improvement in progression-free survival (PFS) for patients.

These late-breaking data are being presented for the first time in a scientific plenary at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer and are also being published simultaneously in the New England Journal of Medicine.

The results are being discussed with regulatory authorities around the world.


Copyright (c) 2023 CercleFinance.com. All rights reserved.